-6.5 | | TAF1L | 'ZEB1 knockout' vs 'wild type' | genotype | Ampliseq transcriptomic array of REF seq. genes in ZEB1 knock out triple negative breast cancer cells |
4.8 | | TAF1L | 'triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
3.6 | | TAF1L | 'sulforaphane; prostate carcinoma' at '24 hour' vs 'sulforaphane; normal' at '24 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
3.5 | | TAF1L | '501Mel; shBRG1 knockdown' vs '501Mel; control' | cell line, phenotype | BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) |
-3.3 | | TAF1L | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
3.3 | | TAF1L | 'arsenite' vs 'control' | compound | Transcription profiling by high throughput sequencing of 293S cells treated with arsenite |
3.3 | | TAF1L | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
3.1 | | TAF1L | 'induced into senescence; 5-aza-2-deoxycytidine' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
3.1 | | TAF1L | 'DNMT1 homozygous knockout' vs 'wild type' | phenotype | RNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations |
2.8 | | TAF1L | 'small cell lung carcinoma' vs 'normal' | disease | RNA-seq of primary tumors from 79 small cell lung cancer patients and 7 normal lung tissue |
-2.7 | | TAF1L | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.6 | | TAF1L | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.6 | | TAF1L | 'DMSO' in 'stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '6 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
-2.6 | | TAF1L | 'EGR2-E356K' vs 'wild type genotype' | genotype | RNA-sequencing of human B cells to investigate chronic lymphocytic leukemia mutations observed in hematopoietic multipotent progenitor fractions |
-2.5 | | TAF1L | 'hepatobiliary carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2.4 | | TAF1L | 'osteosarcoma' vs 'normal' | disease | Transcription profiling by array of human bone specimens from patients with osteosarcoma |
-2.3 | | TAF1L | 'ulcerative colitis' vs 'normal' | disease | PSC-IBD mucosal biology |
2 | | TAF1L | 'blood alcohol content 0%' vs 'control' in 'time point 1' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
2 | | TAF1L | 'blood alcohol content 0.02%declining' vs 'control' in 'time point 5' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
-2 | | TAF1L | 'EX00000246; stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '6 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
2 | | TAF1L | 'tumor tissue' vs 'non-malignant tissue' | sampling site | RNA-seq of 199 non-small cell lung carcinoma patients and 19 paired normal lung tissues |
1.9 | | TAF1L | 'blood alcohol content 0.04%declining' vs 'control' in 'time point 4' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
-1.9 | | TAF1L | 'EX00000246' vs 'none' in 'unstimulated' at '6 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1.8 | | TAF1L | 'medulloblastoma, large-cell' vs 'normal' | disease | Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes |
1.7 | | TAF1L | 'blood alcohol content 0.04%rising' vs 'control' in 'time point 2' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.6 | | TAF1L | 'blood alcohol content 0.08%' vs 'control' in 'time point 3' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.6 | | TAF1L | 'embryonic stem cell differentiating toward definitive endoderm; 60 hour' vs 'embryonic stem cell; 0 hour' | cell type, time | RNA-seq of definitive endoderm differentiation of human embryonic stem cells in early G1 phase of the cell cycle |
-1.5 | | TAF1L | 'familial hemophagocytic lymphohistiocytosis 5' vs 'normal' | disease | RNAseq on PBMC of three patients with Familial Hemophagocytic Lymphohistiocytosis Type 5 (FHL5) and three age and sex-matched controls |
1.4 | | TAF1L | 'differentiated; hAKPC-P' vs 're-differentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
1.3 | | TAF1L | 'differentiated; hAKPC-P' vs 'undifferentiated; hIPod' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
1.3 | | TAF1L | 'differentiated; hAKPC-P' vs 'undifferentiated; hAKPC-P' | cell type, phenotype | Differentiation of human amniotic fluid kidney progenitor cells into podocytes and comparison with human conditionally immortalized podocytes |
1.3 | | TAF1L | 'Zaire ebolavirus lacking the mucin domain of GP' vs 'mock' at '8 hour' | infect, time | Human U937 cell transcriptome response to Zaire Ebola virus wild-type in the delta-VP30 background and delta-mucin virus |
1.3 | | TAF1L | '7 hour' vs '0 hour' in 'MDA-LM2' | cell line, time | Transcription profiling by high throughput sequencing in MDA-MB-231 and MDA-LM2 cell lines |
1.2 | | TAF1L | 'glioblastoma' vs 'normal' | disease | Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes |
1.2 | | TAF1L | 'atypical teratoid / rhabdoid tumor' vs 'normal' | disease | Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes |
1.2 | | TAF1L | 'medulloblastoma' vs 'normal' | disease | Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes |
-1.1 | | TAF1L | 'suberoylanilide hydroxamic acid' vs 'control' | compound | Vascular histone deacetylation by pharmacological HDAC inhibition [SAHA, RNA-seq] |
-1.1 | | TAF1L | 'siRNAs against NELF' vs 'control' in 'whole-cell RNA' | RNA, RNA interference | Integrator complex regulates NELF-mediated RNA Polymerase II pause/release and processivity at coding genes [RNA-seq] |
1 | | TAF1L | 'adult high grade glioma' vs 'normal' | disease | Gene expression profile of pediatric and adult brain tumor types and normal brain |
1 | | TAF1L | 'group 4 medulloblastoma' vs 'normal' | disease | Gene expression profile of pediatric and adult brain tumor types and normal brain |
